$5.00
0.00% day before yesterday
NYSE, May 19, 03:30 pm CET
ISIN
US9013841070
Symbol
TSVT
Sector
Industry

2seventy bio Stock price

$5.00
+0.01 0.20% 1M
+1.89 60.77% 6M
+2.06 70.07% YTD
+0.62 14.16% 1Y
-7.35 59.51% 3Y
-8.77 63.69% 5Y
-8.77 63.69% 10Y
NYSE, Closing price Tue, May 20 2025
+0.00 0.00%
ISIN
US9013841070
Symbol
TSVT
Sector
Industry

Key metrics

Market capitalization $266.15m
Enterprise Value $335.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.94
P/S ratio (TTM) P/S ratio 5.50
P/B ratio (TTM) P/B ratio 1.23
Revenue growth (TTM) Revenue growth -32.07%
Revenue (TTM) Revenue $48.37m
EBIT (operating result TTM) EBIT $-59.35m
Free Cash Flow (TTM) Free Cash Flow $-54.19m
Cash position $170.38m
EPS (TTM) EPS $-0.10
P/E forward negative
P/S forward 3.50
EV/Sales forward 4.41
Short interest 5.07%
Show more

Is 2seventy bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

2seventy bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast 2seventy bio:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast 2seventy bio:

Hold
100%

Financial data from 2seventy bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
48 48
32% 32%
100%
- Direct Costs 28 28
3% 3%
58%
20 20
54% 54%
42%
- Selling and Administrative Expenses 39 39
23% 23%
82%
- Research and Development Expense 33 33
83% 83%
69%
-53 -53
74% 74%
-109%
- Depreciation and Amortization 6.63 6.63
35% 35%
14%
EBIT (Operating Income) EBIT -59 -59
72% 72%
-123%
Net Profit -4.09 -4.09
98% 98%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about 2seventy bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

2seventy bio Stock News

Neutral
Business Wire
13 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. “We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer,” said Chip Baird, chief executive officer, 2seventy bio. “Over the past four years we have de...
Neutral
Business Wire
about one month ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that ...
Neutral
Business Wire
about 2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. “2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure and focus solely on Abecma,” said Chip Baird, chief executive officer, 2seventy bio. “This week ...
More 2seventy bio News

Company Profile

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Head office United States
CEO Chip Baird
Employees 65
Founded 2021
Website www.2seventybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today